NJ State Employees Deferred Compensation Plan continued to hold its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 40,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. NJ State Employees Deferred Compensation Plan’s holdings in Achillion Pharmaceuticals were worth $184,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ACHN. Deschutes Portfolio Strategy LLC boosted its position in Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 3,000 shares during the period. Teza Capital Management LLC bought a new position in Achillion Pharmaceuticals during the first quarter worth about $131,000. Dynamic Technology Lab Private Ltd bought a new position in Achillion Pharmaceuticals during the first quarter worth about $138,000. Highbridge Capital Management LLC bought a new position in Achillion Pharmaceuticals during the first quarter worth about $149,000. Finally, Canada Pension Plan Investment Board boosted its position in Achillion Pharmaceuticals by 4.7% in the first quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,600 shares during the period. 70.83% of the stock is currently owned by institutional investors.

Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) opened at 4.43 on Friday. Achillion Pharmaceuticals, Inc. has a 12 month low of $3.15 and a 12 month high of $9.49. The company has a 50-day moving average of $4.37 and a 200 day moving average of $4.12. The company’s market cap is $605.85 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). During the same quarter in the previous year, the firm posted ($0.14) EPS. On average, equities analysts forecast that Achillion Pharmaceuticals, Inc. will post ($0.67) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Stake Maintained by NJ State Employees Deferred Compensation Plan” was first reported by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/achillion-pharmaceuticals-inc-nasdaqachn-stake-maintained-by-nj-state-employees-deferred-compensation-plan.html.

A number of research firms have recently issued reports on ACHN. Maxim Group set a $7.00 price objective on shares of Achillion Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday. Robert W. Baird cut shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price objective on the stock. in a research report on Thursday. BidaskClub cut shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Chardan Capital cut their price objective on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, Zacks Investment Research cut shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Achillion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $8.25.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.